Evidence map›Paper›PMID 40242413›Full record

ArticleReports of practical oncology and radiotherapy : journal of Greatpoland Cancer Center in Poznan and Polish Society of Radiation Oncology2025

Exploring vimentin expression and its protein interactors across diverse cancer types via the cancer genome atlas datasets: a comprehensive analysis.

Małgorzata Blatkiewicz, Piotr Białas, Olga Taryma-Leśniak, Szymon Mazgaj, Beata Hukowska-Szematowicz, Anna Jankowska

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Reports of practical oncology and radiotherapy : journal of Greatpoland Cancer Center in Poznan and Polish Society of Radiation Oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Małgorzata BlatkiewiczDepartment of Histology and Embryology, Poznan University of Medical Sciences, Poznań, Poland.
Piotr BiałasChair and Department of Cell Biology, Poznan University of Medical Sciences, Poznań, Poland.
Olga Taryma-LeśniakIndependent Clinical Epigenetics Laboratory, Pomeranian Medical University, Szczecin, Poland.
Szymon MazgajInstitute of Biology, University of Szczecin, Szczecin, Poland.
Beata Hukowska-SzematowiczInstitute of Biology, University of Szczecin, Szczecin, Poland.
Anna JankowskaChair and Department of Cell Biology, Poznan University of Medical Sciences, Poznań, Poland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: The global burden of cancer is escalating, with millions of individuals diagnosed and succumbing to the disease each year. Early detection is crucial for improving patient outcomes, yet many cancers are identified at advanced stages. Vimentin (VIM) has emerged as a promising biomarker with significant diagnostic and prognostic potential. Materials and methods: This study investigates Results: Our findings reveal that Conclusion: These insights emphasize Vimentin's multifaceted role in cancer, suggesting its potential as both a therapeutic target and a diagnostic marker.

Indexed as

biomarkercancerexpressionmethylationSTRINGTCGAvimentin

Identifiers

PMID40242413
PMCPMC11999022

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.